Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8530945 | International Immunopharmacology | 2018 | 6 Pages |
Abstract
Thyroid cancer is one of the malignancies with better clinical outcomes. However, a minority of patients develops an aggressive anaplastic thyroid carcinoma. Development of innovative and multimodal therapeutic strategies is urgently needed. Here, we investigated the role of CXCR5+ CD8 T cells in the peripheral blood, tumor-involved lymph nodes (TILN), and tumor mass of thyroid cancer patients. In peripheral blood mononuclear cells, CXCR5+ cells represented 1.4%â¯Â±â¯0.84% (meanâ¯Â±â¯s.d.) of total CD8 T cells, while in TILN and in tumor, the frequencies of CXCR5+ CD8 T cells were significantly higher at 27.7%â¯Â±â¯7.8% and 15.5%â¯Â±â¯2.9%, respectively. Compared to CXCR5â CD8 T cells, CXCR5+ CD8 T cells presented significantly higher PD-1 expression and lower or comparable TIM-3 and CTLA-4 expression. To compare and contrast the functional characteristics of CXCR5+ CD8 T cells and CXCR5â CD8 T cells, these cells were separated from TILNs and were TCR-stimulated via anti-CD3/CD28. Upon stimulation, CXCR5+ CD8 T cells presented stronger downregulation of CD27, higher expression of proinflammatory cytokines IL-2, IFN-γ, and TNF-α, and higher proliferation capacity than CXCR5â CD8 T cells. Moreover, CXCR5+ CD8 T cells presented higher expression of cytotoxic molecules Gzm-A, Gzm-B, and perforin. Overall, these results demonstrated that in thyroid cancer patients CXCR5+ CD8 T cells infiltrated the TILNs and the tumors, and were functionally more potent compared to their CXCR5â counterpart.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Yu Zhou, Linqi Guo, Huawei Sun, Jianbo Xu, Tu Ba,